Author:
El-Shabrawi Mortada H.,Abdo Alaa M.,El-Khayat Hisham R.,Yakoot Mostafa
Publisher
Ovid Technologies (Wolters Kluwer Health)
Subject
Gastroenterology,Pediatrics, Perinatology, and Child Health
Reference8 articles.
1. Electronic address: easloffice@easloffice.eu. EASL Recommendations on Treatment of Hepatitis C 2016;J Hepatol,2017
2. Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis;Kowdley;N Engl J Med,2014
3. Realworld effectiveness of ledipasvir/sofosbuvir (LDV/SOF) in treatment-experienced cirrhotic genotype 1 patients with chronic hepatitis C: a comparative analysis of Gilead sponsored trials with 4 real-world cohorts;Curry;J Hepatol,2016
4. Response tailored protocol versus the fixed 12 weeks course of dual sofosbuvir/daclatasvir treatment in Egyptian patients with chronic hepatitis C genotype-4 infection: a randomized, open-label, non-inferiority trial;Yakoot;EBioMedicine,2017
5. Bioequivalent pharmacokinetics for generic and originator hepatitis C direct acting antivirals: ePoster at The AASLD-The Liver Meeting 2017, Abstract # 1078;Hill;Hepatology,2017
Cited by
32 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献